The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Osteoporosis in Men
Abstract
Osteoporosis has received increasing attention as one of the major disorders of our time. With over 20 million women at risk for fracture, and over 1 million fractures occurring annually, the importance of this disease cannot be overstated. The health care bill attributed to osteoporosis is well over 20 billion dollars. Moreover, fractures associated with osteoporosis, especially hip fracture, can lead to devastating effects on the quality of life, with many individuals unable to resume their former life style and requiring ongoing assistance thereafter. Thus, the table is set for a major thrust on this disease. Pharmaceutical companies are investing untold resources in the search for therapies, foundations are spreading the word among the public, and funding agencies such as the NIH are committed to an investigative agenda to gain key insights into bone biology and mechanisms associated with bone loss. This good news augurs well for the future. Typical of our gender-oriented focus upon many diseases, however, the spotlight on osteoporosis has been on women, simply because women are much more likely to develop osteoporosis than men. This relative exclusivity has delayed progress in understanding the counterpart syndrome, osteoporosis in men. However, osteoporosis in men is not rare, nor are its consequences (1). This state of affairs is reminiscent of a decade ago when heart disease was considered to be primarily a disorder of males. With very little attention given to heart disease in women, it was also mistakenly assumed that what would be learned about male heart disease would automatically apply to female heart disease. Such erroneous assumptions have also been made in the field of osteoporosis; what we know about the female skeleton is often uncritically applied to the male skeleton. Alternatively, and also incorrect, what we know about the female skeleton has been regarded by some as nonoperative in men, simply because men with osteoporosis present differently. Nevertheless, despite the pace, we are slowly learning about osteoporosis in men. It clearly is a pervasive disorder and in a number of respects is different from the disease in women. The purpose of this commentary is to place the available information about male osteoporosis into a practical and informative perspective. The number of men afflicted with osteoporosis is unknown. If one uses fracture as a clear end point, estimates of lifetime risk range from 13–25% (1). This is lower than estimates for Caucasian women, in whom lifetime fracture risk approaches 50%. The diagnosis of osteoporosis, however, no longer depends upon the end result of the disease process. The advent of quantitative imaging technology has allowed us to discover the population at risk before fractures occur. For men and women, fracture risk is directly related to bone mass. Using the WHO guidelines, osteoporosis is present if bone mineral density (BMD) is more than 2.5 sd below the peak bone mass reference standard for young women. When this criterion is applied to women in the United States, 4–6 million women have osteoporosis, and an additional 13–17 million women have osteopenia (BMD between 1–2.5 sd below peak bone mass). The respective age-adjusted prevalence figures are 18% and 50%. If one uses the same criterion for men, namely 2.5 sd below the peak bone mass reference standard for young men, 1–2 million men have osteoporosis, and another 8–13 million have osteopenia. The respective age-adjusted prevalence figures are 6% and 47%. It is not clear, however, whether the same cut-off values should be used, because men achieve more peak bone mass than women and have larger bones, two points that could argue that for the same percent reduction from the gender-based reference standard there would be fewer fractures in men. On the other hand, if one applies the female reference standard to men (2.5 sd below peak bone mass for women), the numbers become much smaller, namely 0.3–1 million men with osteoporosis (age-adjusted prevalence, 4%) and 4–9 million with osteopenia (age-adjusted prevalence, 33%). In either event, the proportion of men with osteoporosis or reduced bone mass relative to the entire population is substantial. Another key factor that tends to keep incidence figures below those for women is that men tend to develop osteoporosis later in life, by about a decade. As the male life span is shorter than the female life span, it has been quipped that men do not live long enough to sustain the complications of osteoporosis. For the same reason, however, namely that complications occur later in life, when men do sustain a hip fracture, associated mortality figures tend to be much higher than those in women. However the incidence figures and diagnostic criteria are viewed, it is true that men in western countries are less likely to develop osteoporosis than women. Men achieve greater peak bone mass than women, by about 8–10%, when areal density is measured. A large
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Professor Kanis, J. A., Melton, L. J., Christiansen, C., Johnston, C. C., & Khaltaev, N. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090802 · Cited by 3,849
Estrogen Resistance Caused by a Mutation in the Estrogen-Receptor Gene in a Man
Smith, E. P., Boyd, J., Frank, G. R., Takahashi, H., Cohen, R. M., Specker, B., Williams, T. C., Lubahn, D. B., & Korach, K. S. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410203311604 · Cited by 2,471
Morishima, A., Grumbach, M. M., Simpson, E. R., Fisher, C., & Qin, K. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.12.8530621 · Cited by 1,416
Effect of testosterone and estradiol in a man with aromatase deficiency
Carani, C., Qin, K., Simoni, M., Faustini-Fustini, M., Serpente, S., Boyd, J., Korach, K. S., & Simpson, E. R. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707103370204 · Cited by 1,151
Long-term effect of testosterone therapy on bone mineral density in hypogonadal men
Behre, H. M., Kliesch, S., Leifke, E., Link, T. M., & Nieschlag, E. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.8.4163 · Cited by 559
Cited by
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Pathophysiology of Osteoporosis
Armas, L. A. G., & Recker, R. R. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.04.006 · Cited by 466
Longitudinal Association between Sex Hormone Levels, Bone Loss, and Bone Turnover in Elderly Men
Gennari, L., Merlotti, D., Martini, G., Gonnelli, S., Franci, B., Campagna, S., Lucani, B., Dal Canto, N., Valenti, R., Gennari, C., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030736 · Cited by 235
Management of Complications of Prostate Cancer Treatment
Michaelson, M. D., Cotter, S. E., Gargollo, P. C., Zietman, A. L., Dahl, D. M., & Smith, M. R. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2008.0002 · Cited by 196
BMD Is Reduced in HIV-Infected Men Irrespective of Treatment
Amiel, C., Ostertag, A., Slama, L., Baudoin, C., N'Guyen, T., Lajeunie, E., Neit-Ngeilh, L., Rozenbaum, W., & De Vernejoul, M. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0301246 · Cited by 150
Metadata
- Authors
- Bilezikian, J. P.
- Venue
- Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1999-10-01
- Volume
- 84
- Issue
- 10
- Pages
- 3431-3434
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W3022800007
- Cited by
- 249
- References
- 5
- FWCI
- 10.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Osteoporosis in Men. https://app.cochat.ai/papers/10.1210/jc.84.10.3431
- The paper
- Bilezikian, J. P. (1999). Osteoporosis in Men. Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.84.10.3431
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.